Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.

Sam Schulman, Henry Eriksson, Samuel Z. Goldhaber, Ajay K Kakkar, MD, PhD, Clive Kearon, Patrick Mismetti, Sebastian M Schellong, David Baanstra, Janet Schnee

Blood (2009) 114 (22): 1.

https://doi.org/10.1182/blood.V114.22.1.1

Published: 2009

Journal Articles

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Sylvia Haas, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, MD, PhD, Bengt Eriksson, MD, PhD, Kai Vogtlaender, Dagmar Kubitza, MD, Wolfgang Mueck, PhD, Michael Gent, DSc, Frank Misselwitz, MD, Scott D Berkowitz, MD, FACP

Blood (2009) 114 (22): 2099.

https://doi.org/10.1182/blood.V114.22.2099.2099

Published: 2009

Journal Articles

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Ajay K. Kakkar, MD, PhD, Benjamin Brenner, MD, Ola E. Dahl, MD, PhD, Bengt I. Eriksson, MD, PhD, Patrick Mouret, MD, Jim Muntz, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD, Sylvia Haas, MD

Blood (2007) 110 (11): 307.

https://doi.org/10.1182/blood.V110.11.307.307

Published: 2007

Journal Articles

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.

Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Richard J. Friedman, MD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Tiemo J. Bandel, MD, Eva Muehlhofer, MD, Frank Misselwitz, MD, William Geerts, MD

Blood (2007) 110 (11): 6.

https://doi.org/10.1182/blood.V110.11.6.6

Published: 2007

Journal Articles

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Wolfgang Mueck, PhD, Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Eva Muehlhofer, PhD, Frank Misselwitz, MD, PhD

Blood (2006) 108 (11): 903.

https://doi.org/10.1182/blood.V108.11.903.903

Published: 2006

Journal Articles

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Alexander G.G. Turpie, MD, Kenneth Alan Bauer, MD, Lars Borris, MD, Ola E. Dahl, MD, PhD, William D. Fisher, MD, Michael Gent, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Louis M. Kwong, MD, Martin Homering, PhD, Frank Misselwitz, MD, PhD, Bengt I. Eriksson, MD, PhD

Blood (2005) 106 (11): 277.

https://doi.org/10.1182/blood.V106.11.277.277

Published: 2005

Journal Articles

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Bengt I. Eriksson, MD, PhD, Lars Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Frank Misselwitz, MD, PhD, Eva Muehlhofer, PhD, Peter Kälebo, MD, PhD

Blood (2005) 106 (11): 280.

https://doi.org/10.1182/blood.V106.11.280.280

Published: 2005

Journal Articles

Rates of Clinically Apparent Venous Thromboembolism and Death Resulting from Pulmonary Embolism among Unselected Hospitalized Acutely Ill Medical Patients Versus Rates Predicted from Clinical Studies.

Franco Piovella, MD, Frederick A. Anderson, Jr., PhD, Hervé Decousus, MD, Gordon FitzGerald, Jean-François Bergmann, MD, Ajay K. Kakkar, MD, PhD, Alex C. Spyropoulos, MD, Rainer B. Zotz, MD, Frederick A. Spencer, MD, Alexander G.G. Turpie, MD, for the IMPROVE Investigators

Blood (2005) 106 (11): 1620.

https://doi.org/10.1182/blood.V106.11.1620.1620

Published: 2005

NARROW

Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Rates of Clinically Apparent Venous Thromboembolism and Death Resulting from Pulmonary Embolism among Unselected Hospitalized Acutely Ill Medical Patients Versus Rates Predicted from Clinical Studies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only